Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
ST. LOUIS, Jan. 27, 2017 -- GeneriCo, LLC (“GeneriCo”), a global generic specialty pharmaceutical company, is pleased to announce that George R. Stevenson has joined the Company’s Board of Directors as the new Chairman of the Board. Mr. Stevenson brings deep generic and brand pharmaceutical expertise to the GeneriCo Board and is a seasoned pharmaceutical executive with many years of leadership in this dynamic marketplace. Mr. Stevenson most recently served as the President and Chief Executive Officer of Kremers Urban Pharmaceuticals (Division of UCB, Inc.) which was acquired in 2015 by Lannett Company, Inc. for $1.23B.
At Kremers Urban, George Stevenson led the Company’s growth from minimal value in 2007 to $1.23 billion in 2015. As part of this growth, Mr. Stevenson oversaw the approval of 12 FDA approved products, with another 30 products added to the R&D portfolio. Prior to Kremers Urban, Mr. Stevenson was Vice President of Generic Business & Trade Affairs at Endo Pharmaceuticals, and prior to that was successful during his professional career at Sandoz Inc. (Division of Novartis AG), Apothecon (Division of BMS), United Research Laboratories and Sun Company.
Tom Brya, CEO GeneriCo, stated, “We are thrilled to add George Stevenson to our Board of Directors. He will bring a depth of generic pharmaceutical expertise and leadership to add to our Board. His guidance will be invaluable as our ANDA pipeline products progress to approval and launch.”
About GeneriCo
GeneriCo is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the U.S. utilizing its proprietary data-driven, algorithm-based product selection process. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st internally-developed ANDA to be filed in 2017, with a total of 2 ANDAs filed by the end of 2017.
GeneriCo is led by a management team with 195 years of combined experience in formulation, manufacturing and commercial leadership. The team has successfully filed and launched over 200 generic drugs and created more than $30B of firm value.
For more information, please visit www.genericopharma.com
GeneriCo Investor Contact: Deborah Knobelman, PhD – Chief Financial Officer Phone Number: +1.646.221.5830 Email: [email protected]
